CHARLESTON, S.C. – According to several reports accumulated by the National Institutes of Health, it’s been found that the SARS-CoV-2 (COVID-19) virus hospital-acquired infection rate is approximately 12-15%. Acquiring any disease within a medical facility is not only dangerous, but can be a public health risk as well. Whether or not hospital-acquired infection is considered a case of malpractice or inevitable in a location such as this, new technology has been produced to help stop the spread of infectious diseases.
Paerolyte is a new organic, non-toxic and powerful liquid disinfectant that when used in Paerosol’s MAG, or micro-aerosol generator, can reach and disinfect all areas of an enclosed space. The micro-aerosol generator uses proprietary technology to evenly distribute the liquid disinfectant using a “dry spray.” The “dry spray” technology turns the liquid into sub-micron particles, allowing it to diffuse into an entire room, while leaving no liquid residue anywhere throughout the enclosed room or space. Paerolyte’s liquid disinfectant can kill up to 99.9999% of viruses, bacteria, and mold – including but not limited to Salmonella, E. Coli and SARS-CoV-21. The use of Paerolyte in conjunction with the Paerosol micro-aerosol generator is a perfect solution for hospitals, labs, and other “clean” areas that need to stay that way.
“Paerosol killed four (4) of the most common causes of Hospital Acquired Infections.”
- S. Defence Threat Reduction Agency
“We’ve seen amazing test results with the Paerolyte liquid disinfectant in conjunction with the Paerosol micro-aerosol generator. It’ll revolutionize how santitization takes place in all types of medical facilities.”
- Steve Gareleck, CEO of Paerosol LLC
About Paerosol – Paerosol is a platform which kills air and surface-borne mold, bacteria, and viruses at up to a 99.9999% rate of effectiveness. The Paerosol technology originated in the Department of Energy’s Pacific Northwest National Laboratory (“PNNL”) which is managed and operated by Battelle Memorial Institute. As part of the Federal Lab Commission’s (“FLC”) efforts to commercialize federally owned technology within the private sector, Paerosol LLC (founded by Steve Gareleck, CEO and Scott Alderson, President) obtained the exclusive licensing rights to this disinfecting technology directly from Department of Energy’s Pacific Northwest National Laboratory. Paerosol’s proprietary Dry Spray technology allows for Paerolyte’s liquid disinfectant to get into all corners and crevices of any space it’s placed in. Paerosol has been successfully tested by US & Foreign Government Agencies. The United States Defense Threat Reduction Agency successfully tested Paerosol against bio-agents including simulates of Anthrax and Ebola, common civilian and hospitals pathogens such as E Coli and Salmonella, antibiotic-resistant microbes, and viruses including H1N1 (swine flu), H5N1 (bird flu), MRSA, and the SARS-CoV-2 virus (COVID-19)2.
- https://www.paerosol.com/wp-content/uploads/2020/03/PNNL-Paerosol-all-study-summary-from-BATTELLE-DoE.pdf, Pages 12 – 15
- National Research Council. 2013. The Unique U.S.-Russian Relationship in Biological Science and Biotechnology: Recent Experience and Future Directions. Washington, DC: The National Academies Press. https://doi.org/10.17226/18277. 153.
Contact Information:
info@paerosol.com (843) 535 – 0500.
Tags:
Financial Content, PR-Wirein, Google News, Reportedtimes, Menafn, IPS, iCN Internal Distribution, Legal Newswire, Environmental regulations, English
Contact Information:
info@paerosol.com
(843) 535 – 0500.
The post Hospitals to use new disease killing technology appeared first on Financial Market Brief.
